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Dual orexin receptor (OXR) antagonists (DORAs) such as almorexant, SB-649868,
suvorexant (MK-4305), and filorexant (MK-6096), have shown promise for the treatment of
insomnias and sleep disorders. Whether antagonism of both OX1R and OX2R is necessary
for sleep induction has been a matter of some debate. Experiments using knockout mice
suggest that it may be sufficient to antagonize only OX2R. The recent identification of
an orally bioavailable, brain penetrant OX2R preferring antagonist 2-((1H-Indol-3-yl)methyl)-
9-(4-methoxypyrimidin-2-yl)-2,9-diazaspiro[5.5]undecan-1-one (IPSU) has allowed us to test
whether selective antagonism of OX2Rmay also be a viable strategy for induction of sleep.
We previously demonstrated that IPSU and suvorexant increase sleep when dosed during
the mouse active phase (lights off); IPSU inducing sleep primarily by increasing NREM
sleep, suvorexant primarily by increasing REM sleep. Here, our goal was to determine
whether suvorexant and IPSU affect sleep architecture independently of overall sleep
induction. We therefore tested suvorexant (25mg/kg) and IPSU (50mg/kg) in mice during
the inactive phase (lights on) when sleep is naturally more prevalent and when orexin
levels are normally low. Whereas IPSU was devoid of effects on the time spent in NREM
or REM, suvorexant substantially disturbed the sleep architecture by selectively increasing
REM during the first 4 h after dosing. At the doses tested, suvorexant significantly
decreased wake only during the first hour and IPSU did not affect wake time. These data
suggest that OX2R preferring antagonists may have a reduced tendency for perturbing
NREM/REM architecture in comparison with DORAs. Whether this effect will prove to be
a general feature of OX2R antagonists vs. DORAs remains to be seen.
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INTRODUCTION
Since the link between the hypocretin/orexin system and sleep
disorders was discovered (Chemelli et al., 1999; Lin et al., 1999;
Nishino et al., 2000), there has been much interest in developing
orexin receptor antagonists (ORAs) for the treatment of insom-
nia. Several dual orexin receptor antagonists (DORAs) have now
been tested in the clinic and have demonstrated sleep inducing
properties in healthy volunteers and/or in patients suffering from
insomnia (Brisbare-Roch et al., 2007; Winrow et al., 2011; Bettica
et al., 2012a). Whereas ORAs are expected to be without the side
effects characteristic of currently available treatments, questions
about mechanism related safety have accompanied their devel-
opment. As the lack of orexin signaling causes narcolepsy with
cataplexy, there is concern that DORAsmay induce sudden loss of
motor control or sleep attacks. Whereas the therapeutic potential
for treating insomnia with ORAs is undisputedly high, there is
less consensus regarding the necessity of targeting both receptors
and whether selective antagonists might reduce potential safety
concerns without loss of efficacy (Mieda et al., 2013).
Several lines of evidence suggest that selective OX2R antag-
onists may be sufficient for sleep induction and may have a
reduced tendency for induction of cataplexy and/or narcolepsy
in comparison with DORAs. In knockout mice, the sleep induc-
ing properties of the DORA almorexant require intact OX2Rs
but not OX1Rs (Mang et al., 2012). Also, selective OX2R antag-
onists induce sleep in rats and mice, whereas OX1R selective
antagonists do not [(Dugovic et al., 2009; Steiner et al., 2013);
but see Morairty et al. (2012)]. Together these findings strongly
suggest that antagonizing OX2R may be sufficient for sleep
induction.
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In humans, orexin deficiency leads to narcolepsy with cata-
plexy (Nishino et al., 2000). The narcolepsy/cataplexy phenotype
is mimicked in mice lacking orexin peptides, lacking orexinergic
neurons or mice lacking both orexin receptors (OXR) (Chemelli
et al., 1999; Hara et al., 2001; Kalogiannis et al., 2011). Although
mice lacking OX2R also have sleep attacks, the incidence of cat-
aplexy in these mice is close to null (Willie et al., 2003). Thus,
there may be a reduced risk of inducing cataplectic events when
only OX2R are antagonized. In dogs, mutations in OX2R alone are
sufficient to cause narcolepsy with cataplexy. Interestingly, spo-
radic narcolepsy with cataplexy in dogs is associated with orexin
deficiency resulting in more severe symptoms than the OX2R
mutations (Baker et al., 1982; Ripley et al., 2001). It is tempt-
ing to speculate that OX2R antagonists might be less prone to
induce symptoms similar to either narcolepsy or cataplexy than
DORAs even in this very sensitive species. To date, although
functionally relevant polymorphisms of the OXRs have been
described in humans (Thompson et al., 2004; Rainero et al., 2008;
Annerbrink et al., 2011), mutations of the receptors have not
been linked to narcolepsy/cataplexy. Rather loss of the orexin-
ergic neurons or, extremely rarely, mutations resulting in loss
of the peptides have been reported to be the underlying cause
(Peyron et al., 2000; Thannickal et al., 2000). Together, such
findings suggest it may be a general rule that loss of OX2R sig-
naling has a reduced propensity for inducing narcolepsy and/or
cataplexy as compared to loss of the entire orexin signaling
pathway.
We have therefore been interested in determining whether
antagonists of OX2R are comparable to DORAs in their ability to
induce sleep. Recently, we identified the orally bioavailable, brain
penetrating OX2R preferring antagonist IPSU that induces sleep
when administered at the start of the active (dark) phase in mice
(Betschart et al., 2013). The aim of the present study was to inves-
tigate whether IPSU and the DORA suvorexant affect the natural
sleep architecture, by testing low doses of the two compounds
during the light phase whenmice are primarily inactive and spend
a high proportion of the time sleeping.
METHODS
All experiments were performed according to Swiss guidelines
and law and were approved by the Veterinary Authority of Basel-
Stadt, Switzerland. Every effort was made to minimize the num-
ber of animals used and to minimize any pain or discomfort.
Male C57Bl/6mice weighing 25–35 g were single or group-housed
on wood shavings in type II (14 × 16 × 22 cm) and type III
(15 × 22 × 37 cm) cages, respectively. Each cage contained a nest
box, a piece of wood and tissue paper nesting materials, and ani-
mals had access to food and water ad libitum. The housing cages
were placed in a temperature and humidity controlled room (20–
24◦C, 45% humidity) with a light/dark cycle of 12:12 (lights on at
03:00, max 80 Lux).
Suvorexant and IPSU were both synthesized and purified
in house according to published procedures (Cox et al., 2008;
Betschart et al., 2013). We selected doses that were effective at
promoting sleep in mice for the first 4 h when administered at
the start of the dark phase [Betschart et al. (2013) and unpub-
lished observations]. At the mouse OXRs, IPSU has about 6.2×
higher affinity at OX2R than OX1R (pKd OX1R 6.34, OX2R
7.23) whereas suvorexant is about 6.5× more potent at OX1R
than OX2R [pKd OX1R 8.77, OX2R 8.06; FLIPR assay Callander
et al. (2013)]. Both compounds are highly brain penetrant. One
hour after oral dosing of 50mg/kg, brain levels reached 8778
pmol/g for IPSU and 10329 pmol/g for suvorexant giving free
levels of 53.6 and 67.0 pmol/g, respectively (Betschart et al.,
2013). In the present study we decided to dose IPSU at the
previously effective dose of 50mg/kg and to reduce suvorex-
ant to 25mg/kg to better match the estimated OX2R occupancy.
At 1 h following 25mg/kg suvorexant brain levels reached 3605
pmol/g and free levels were therefore 23.4 pmol/g. Estimating
the available antagonist concentrations to be 53.6 and 23.4 nM
for IPSU and suvorexant, we estimated receptor occupancies
according to:
Bound = Bmax/(1 + Kd/L)
where Bmax is 100%, Kd the affinity from the FLIPR assay, and L
the free brain concentrations at the doses tested.
The expected occupancies of suvorexant are therefore 93% at
OX1R, 73% at OX2R and for IPSU 11% at OX1R and 48% at
OX2R. These values are similar to the effective values for sleep
induction at OX2R reported by Gotter et al. (2013).
IMPLANTATION OF ELECTROCORTICOGRAM/
ELECTROENCEPHALOGRAM (EEG) AND ELECTROMYOGRAM (EMG)
ELECTRODES
Mice were administered buprenorphine (0.05mg/kg s.c.) 1 h
before surgery, anesthetized with ketamine/xylazine (110mg/kg,
10:1, i.p.) and placed in a stereotaxic frame. The skull was
exposed and four miniature stainless steel screws (SS-5/TA
Science Products GmbH, Hofheim, Germany) attached to 36-
gauge, Teflon-coated solid silver wires were placed in contact
with the frontal and parietal cortex (3mm posterior to bregma,
±2mm from the sagittal suture) through bore holes. The frontal
electrodes served as reference. The wires were crimped to a small
6-channel connector (CRISTEKMicro Strip Connector) that was
affixed to the skull with dental acrylic. Electromyograph (EMG)
signals were acquired by a pair of multistranded stainless steel
wires (7SS-1T, Science Products GmbH, Hofheim, Germany)
inserted into the neck muscles and also crimped to the head-
mount. After surgery, mice were kept singly in cages and allowed
to recover on a heating pad. Buprenorphine, 0.05mg/kg, s.c. was
given 8 and 16 h after surgery to control pain. After 24 h, the mice
were housed with their former cage mates and allowed to recover
for 2 weeks.
SLEEP STUDIES
Mice were habituated to individual cages in a sound-attenuated
recording chamber for 6–10 days (lights on 03:00, lights off 15:00,
max 80 lux) at a temperature of about 23◦C. During the stud-
ies, mice had access to food and water ad libitum, to one sheet
of nesting paper and a piece of wood but no nesting box. Mice
were weighed and attached to recording cables that connected
their headmounts to a commutator (G-4-E, Gaueschi) allowing
free movement in the experiment boxes, 1 day before beginning
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the experiment. The recording chamber was opened each day dur-
ing the light period between 08:00 and 09:00 to care for the mice
and all experimental manipulations and oral applications were
performed in a time window of 5–15min before the start of the
recordings at 09:00, exactly 6 h after lights on. Day 1, the mice
were manipulated and habituated to the oral application syringe.
Day 2, they received vehicle (methylcellulose 0.5%, 10mL/kg, per
os). Day 3, 50mg/kg IPSU or 25mg/kg suvorexant was adminis-
tered per os. Recordings began at 09:00 (hour 0) and continued for
23 h. The experimental chamber was secured about 5min prior
to start of the recordings and the mice remained undisturbed for
the next 23 h. On Day 4, the mice were returned to their nor-
mal housing cages for at least 2 weeks before returning to the
experiment.
EEG/EMG signals were amplified using a Grass Model 78D
amplifier (Grass Instrument CO., Quincy, MA, USA), analog
filtered (EEG: 0.3–30Hz, EMG: 5–30Hz) and acquired using
Harmonie V5.2 (acquisition frequency: 200Hz with calibration
the first day, record duration: 23h). Animals were video recorded
during data collection, using an infrared video camera and loco-
motor activity was detected using infrared sensors (InfraMot
Infrared Activity Sensor 30-2015 SENS, TSE Systems) placed in
the roof of the boxes. Activity signals were acquired in 10 s inter-
vals by the software Labmaster V2.4.4. EEG/EMG and activity
recordings were imported into and scored in 10 s epochs using
the rodent scoring module of Somnologica into wake, NREM
sleep and REM sleep. Epochs during which there were state tran-
sitions were scored as the state present for at least 50% of the
epoch. The time in each state per hour was calculated andmean±
s.e.m. is shown. Restricted maximum likelihood analysis (REML)
was applied to the data from the first 6 h to determine if there
was a statistically significant effect of treatment or a significant
interaction between treatment and hour. When either treatment
or the interaction was significant (p < 0.05), post-hoc Fisher’s
Least Significant Difference (LSD) tests were applied to determine
hour by hour where there were significant differences between the
vehicle and compound days.
The first 2 h following drug treatment were, in addition, man-
ually scored to assess sleep-wake transitions including very short
awakenings i.e., those with durations of 1–5 s that are often seen
in mice and which would not be detected using 10 s epochs.
RESULTS
The ORA IPSU (50mg/kg) had no effect on the sleep archi-
tecture of mice when administered during the middle of the
light phase (Figures 1A,C). The amount of time spent in wake,
NREM and REM were unchanged following administration of
IPSU relative to the previous day when vehicle was administered
[treatment: wake F(1, 120) = 0.002, p = 0.96, NREM F(1, 120) =
0.002, p = 0.97, REM F(1, 120) = 0.001, p = 0.97, treatment ×
hour: wake F(5, 120) = 0.59, p = 0.71, NREM F(5, 120) = 0.56,
p = 0.73, REM F(5, 120) = 0.44, p = 0.82, REML].
FIGURE 1 | Sleep architecture during the inactive period is
perturbed by a DORA but not by an OX2R antagonist in C57Bl/6
mice. (A) EEG/EMG/motility signals were used to score vigilance
states into wake, NREM and REM beginning from time 0, 6 h into
the light period. Vehicle (0.5% methylcellulose in water) or 50mg/kg
IPSU were applied per os 5–15min prior to start of the recordings on
successive days (n = 11). The mean ± s.e.m. minutes per hour spent
in each stage are shown. Shading indicates the dark period. (B)
Vehicle (0.5% methylcellulose in water) or 25mg/kg suvorexant were
applied per os 5–15min prior to start of the recordings on successive
days (n = 11). ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 Fisher’s LSD. (C)
Quantification of the effect of IPSU and suvorexant on wake, NREM
and REM during the first 4 h post-treatment. ∗p < 0.05, ∗∗∗p < 0.001
paired t-test drug vs. vehicle.
www.frontiersin.org December 2013 | Volume 7 | Article 235 | 3
Hoyer et al. 2 is better than dual?
In contrast, the DORA suvorexant (25mg/kg) slightly
decreased time spent in wake, had weak effects on time in
NREM but strongly increased the amount of time spent in
REM sleep during the first 4 h immediately following application
[Figures 1B,C, treatment: wake F(1, 120) = 3.4, p = 0.066, NREM
F(1, 120) = 0.44, p = 0.51, REM F(1, 120) = 28.9, p < 0.001, treat-
ment× hour: wake F(5, 120) = 2.31, p = 0.048, NREM F(5, 120) =
1.76, p = 0.13, REM F(5, 120) = 3.37, p = 0.007, REML].
Manual rescoring of the first 2 h after vehicle or drug appli-
cation confirmed that the automatic scoring was in excellent
agreement when amount of time in each stage was compared, bet-
ter than 90% as previously reported by us and others (Pick et al.,
2011; Mang et al., 2012). The number of awakenings was, how-
ever, different. Very short awakenings were found within epochs
scored as NREM (Léna et al., 2004). We therefore used the results
from themanual scoring to quantify the latency to NREMor REM
and the sleep-wake transitions (Table 1).
Both IPSU and suvorexant showed a tendency to shorten the
latency to NREM and REM sleep but only the shortening of
latency to REM by suvorexant was significantly different from
the vehicle. Awakenings from NREM were unaffected by either
compound. Whereas awakenings from REM were significantly
increased by suvorexant, the OX2R antagonist IPSU had no effect.
DISCUSSION
Whereas IPSU did not perturb the normal sleep pattern of mice
during the inactive period, suvorexant profoundly altered the
sleep pattern, doubling the time spent in REM. The latency to
REM and number of awakenings from REM was also selec-
tively increased by suvorexant but not by IPSU. This pattern
is similar to that found when these compounds were dosed
at the start of the dark (active) period in mice (Betschart
et al., 2013). Suvorexant promoted sleep primarily by increas-
ing REM with small effects on NREM and IPSU promoted
sleep primarily by promoting NREM and to a lesser degree
REM (Betschart et al., 2013). The stronger enhancement of
REM vs. NREM by suvorexant has also been seen in rats and
in both healthy humans and humans suffering from insomnia
(Winrow et al., 2011; Herring et al., 2012; Sun et al., 2013).
Interestingly, our findings indicate that this DORA influences
REM independently of the circadian dosing time, increasing the
time in REM during both the light (active) phase and dark
(active) phase whereas, at the dose tested, the OX2R preferring
antagonist IPSU influences sleep only during the active phase
in mice.
Influencing the balance between REM and NREM is an area
of potential differentiation between OX2R preferring antagonists
and DORAs. Classic benzodiazepines, “Z drugs” such as zolpi-
dem, and antidepressants are well known for suppressing REM
sleep whereas ORAs certainly lack this property. Although IPSU
is not highly selective for OX2R vs. OX1R at mouse receptors
(∼6.2×), the opposite is true for suvorexant, which prefers mouse
OX1R vs. OX2R (∼6.5×, Betschart et al., 2013; Callander et al.,
2013). Thus, the balance between antagonism of OX1R and OX2R
may contribute to the differential effects of ORAs on sleep archi-
tecture. Our findings suggest that reducing the level of OX1R
antagonism shifts the sleep balance toward NREM. Supporting
this hypothesis, almorexant induces a greater REM increase in
OX1R−/− than in wildtype mice (Mang et al., 2012). Likewise,
whereas both almorexant and the OX2R antagonist JNJ-10397049
increased NREM during the light phase in rats, only almorexant
also increased REM, and co-application of an OX1R antagonist
significantly reduced the NREM induced by the OX2R antago-
nist (Dugovic et al., 2009). For the most part, DORAs increase
REM more than NREM in rodent studies when % increase
is considered (Brisbare-Roch et al., 2007; Winrow et al., 2011;
Betschart et al., 2013; Black et al., 2013). However, the contri-
bution of REM as a proportion of total sleep time varies for
different compounds. For example, in mice almorexant-induced
increases in REM remain within the proportion seen during
normal sleep, even at high doses (Mang et al., 2012), whereas
suvorexant increases REM proportion much above that seen dur-
ing normal sleep (Betschart et al., 2013). Almorexant is unusual
among the DORAs in that it appears to become a somewhat OX2R
preferring antagonist in vivo. The ex vivo occupancy of almorex-
ant was found to be about 2x higher and much longer lasting
at OX2Rs (>12 h) vs. OX1Rs (Morairty et al., 2012). This pref-
erence is most likely driven by the unusual kinetics (Malherbe
et al., 2009; Mang et al., 2012; Callander et al., 2013) so that with
short exposures the compound may act as a DORA, and when
equilibrium is allowed to be reached almorexant has functional
selectivity for OX2Rs. Evidence against our hypothesis includes
the description of a newer DORA that increases NREM pref-
erentially in rats (Sifferlen et al., 2013). The structure of this
compound is quite similar to that of almorexant but whether the
kinetics also bias it toward OX2R selectivity when equilibrated
Table 1 | Effect of the OX2R preferring antagonist IPSU and the DORA, suvorexant on latency to sleep and sleep to wake transitions during the
first 2 h after administration during the inactive period.
Vehicle IPSU Diff Vehicle Suvorexant Diff
Latency to NREM (minutes) 9.5±3.0 2.6±1.0 −7.0±3.3 13.1±5.9 4.8±1.9 −8.3± 6.3
Latency to REM (minutes) 22.1±3.4 14.5±2.3 −7.6±4.5 37.0±10.1 8.4±2.3* −28.6± 8.8
Awakenings from NREM 25.1±2.6 25.3±2.0 0.2±2.4 19.4±1.6 18.6±1.9 −0.8± 2.4
Awakenings from REM 10.2±0.9 10.8±1.1 0.6±1.1 8.2±1.4 15.6±1.2** 7.4± 1.6
Short awakenings from NREM (<5 s) 23.55±2.8 26.5±4.3 2.9±1.9 25.7±4.0 26.6±3.1 0.9± 2.1
Total awakenings 58.8±4.7 62.6±5.1 3.7±2.7 53.3±4.9 60.8±3.8*** 7.5± 1.9
*p < 0.05, **p < 0.01, ***p < 0.001, paired t-test.
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is unknown. Interestingly, species differences also exist in the
effects of DORAs on sleep architecture. In dogs, suvorexant pre-
dominately increased NREM (Winrow et al., 2011). The effects
of DORAs on REM in humans appear to more closely mimic
the effects in rodents rather than dogs as in the clinical settings,
REM was preferentially enhanced with SB-649868 (Bettica et al.,
2012a,b,c) and suvorexant (Herring et al., 2012; Sun et al., 2013).
With the limited data available, whether the differential effects of
the DORAs and OX2R antagonists on sleep architecture are in
fact due to differences in receptor affinity/occupancy or are due
to other factors such as compound class and species, remains to
be seen as more compounds from different chemical classes are
developed.
Why might a DORA be expected to influence REM
more strongly than an OX2R preferring antagonist?
Intracerebroventicular or local application of orexin-A in
the highly OX1R expressing locus coeruleus reduces REM sleep,
an effect that is blocked by the OX1R antagonist SB-334867
(Smith et al., 2003; Mieda et al., 2011). Additionally, knock-down
of OX1R receptors in the locus coeruleus selectively increases
REM, without affecting NREM during the active phase (Chen
et al., 2010). Interestingly, we did not see a similar dependence
of circadian time on the REM enhancement by suvorexant.
REM sleep is not however, exclusively modulated by OX1Rs.
OX2R knockdown in the lateral pontomesencephalic tegmentum
increased REM both during the active and inactive phases (Chen
et al., 2013) and while OX1R antagonists alone generally do not
induce REM (Steiner et al., 2013), they may increase REM on top
of the effects of OX2R antagonists (Dugovic et al., 2009). Overall,
both OX1R and OX2R when activated or down regulated in the
appropriate regions appear to be able to modulate REM sleep.
However, the modulatory role of OX1R on REM may be greater
than that of OX2R.
In conclusion, we hypothesize that selective OX2R antago-
nists have potential for the treatment of insomnia and may
prove to perturb sleep architecture to a lesser degree than some
of the DORAs. More highly selective antagonists from differ-
ent chemical classes will be required to test this hypothesis
further.
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